Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This research is being done to see if an investigational radioactive imaging agent
(radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the
prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer
before surgery.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins